Approval of basis of allotment under Right issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts more than Nifty Microcap 250 and 6.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lalchandani Labs has completed its rights issue and allotted 43,04,000 equity shares to eligible shareholders and renouncees at ₹10 per share, raising ₹430.40 lakhs. The issue opened on February 4, 2026 and closed on February 27, 2026, with the board approving the allotment on March 2, 2026. The issue was priced at par (face value), with no premium. As a result, the company's paid-up share capital has doubled from ₹4.33 crore to ₹8.64 crore, taking total shares to 86,37,068. The full subscription indicates strong shareholder participation, though pricing at par means no capital appreciation benefit for investors.
The rights issue is now fully allotted, so the share count has nearly doubled, which may lead to short-term price adjustment (ex-rights effect already priced in). Existing shareholders who didn't subscribe have effectively been diluted, while those who subscribed maintain their proportional ownership. With the issue at par, the funds raised will be used for general corporate purposes (not specified in this filing).